About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Gastric Acid Suppression by Proton Pump Inhibitors as an Independent Risk Factor for Clostridium difficile–Associated Diarrhea
In a study that examined whether PPIs were associated with the development of CDAD in hospitalized patients, the authors found that PPIs did not raise the incidence of this disease, which is caused by a prevalent bacterial infection.
Keithen Branch, PharmD, Vince Yahl, PharmD, BCPS, Karen Kier, PhD, MSc, BSPharm, Nancy Mertz, BBA, and Suzanne Marques, PharmD, BCPS
Sessions from three meetings included discussions of arformoterol and indacaterol for chronic obstructive pulmonary disease, pegylated interferon with or without ribavirin and its role in hepatitis C virus infection, ambrisentan for pulmonary arterial hypertension, and olmesartan/amlodipine combinations for hypertension.
Reuben B. David
The author presents a detailed account of the causes, diagnosis, prognosis, and therapies for colorectal cancer, including some promising biologic agents under development.
Marvin M. Goldenberg, PhD, RPh, MS
Author: Robert I. Field, JD, MPH, PhD
Reviewed by Sara Thier, MPH
David Nash, MD, MBA, describes the effectiveness of various interventions in the uphill battle to motivate patients to comply with prescribed medication regimens.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, shows how easy it is to confuse methylprednisolone acetate (Depo-Medrol) with methylprednisolone sodium succinate (Solu-Medrol).
Matthew Grissinger, RPh, FASCP
Stephen Barlas discusses a new Medicaid rule that may result in lower reimbursements to pharmacies for popular generic drugs.
P&T presents the latest studies and information about FDA approvals, drug indications, and industry updates.
Drs. Sherwood, Rey, and Conwell review ramelteon (Rozerem) for patients with insomnia.
Devon A. Sherwood, PharmD, Jose A. Rey, PharmD, BCPP, and Michelle R. Conwell, PharmD